References
- Nitzan U, Lichtenberg P. Questionnaire survey on use of placebo. Br J Med 2004; 329: 944–6
- World Medical Association. Declaration of Helsinki. Edinburgh 2000. Available at, , htpp://www.wma.net. Accessed December 2004.
- International Ethical Guidelines for Biomedical Research Involving Human Subjects, CIOMS 2002, Geneva. ( www.cioms.ch)
- Emmanuel EJ, Miller FG. The ethics of placebo-controlled trials – A middle ground. NEJM 2001; 345: 915–19
- Huston P. What does the public think of placebo use? The Canadian experience. Sci Eng Ethics 2004; 10: 103–17
- The European Agency for the Evaluation of Medical Products. Committee for proprietary medicinal products. 2003. htpp://www.emea.eu.int.
- Hummer M, Holzmeister R, Kemmler G, Eder U, Hofer A, Kurzthaler I, et al. Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry 2003; 64: 277–81
- Roland M, Torgersson DJ. Understanding controlled trials. What are pragmatic trials?. BMJ 1998; 316: 285
- Barbui C, Hotopf M. Forty years of antidepressant drug trials. Acta Psychiatr Scand 2001; 104: 92–5
- Senn S. Individual response to treatment: Is it a valid assumption?. Br J Med 2004; 329: 966–8
- Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: An analysis of the Food and Drug Administration database. Am J Psychiatry 2001; 158: 1449–54
- Storosum JG, Elferink AJA, van Zwieten BJ. Schizophrenia: Do we really need placebo-controlled studies?. Eur Neuropsychopharmacol 1998; 8: 279–86
- Walsh BT, Seidman SN, Sysko R, Goud M. Placebo response in studies of major depression. Variable, substantial, and growing. JAMA 2002; 287: 1840–7
- Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller H-J. Placebo-controlled studies in depression: Necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 2003; 253: 22–8
- Fleischacker WW, Czabor P, Hummer M, Kemmler G, Kohnen R, Volavka J. Placebo or active control trials of antipsychotic drugs. Arch Gen Psychiatry 2003; 60: 458–64
- Spiegel D. Placebos in practice. Br J Med 2004; 329: 927–8
- Senn S. Ethical considerations concerning treatment allocation in drug development trials. Stat Meth Med Res 2002; 11: 403–11
- Welge JA, Keck PE. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: A meta-regression. Psychopharmacology 2003; 166: 1–10
- Greist JH, Mundt JC, Kobak K. Factors contributing to failed trials of new agents: Can technology prevent some problems. J Clin Psychiatry 2002; 63(Suppl 2)8–13
- Schatzberg AF, Kraemer HC. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol Psychiatry 2000; 47: 736–44
- Mattocks KM, Horwitz RI. Placebos, active control groups, and the unpredictability paradox. Biol Psychiatry 2000; 47: 693–8
- Harris EC, Barraclough B. Excess mortality of mental disorders. Br J Psychiatry 1998; 173: 11–53
- Storosum JG, van Zwieten BJ, Wohlfarth T, de Haan L, Khan A, van den Brink. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry 2003; 60: 365–8
- Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Arch Gen Psychiatry 2000; 57: 311–17
- Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: Analysis of FDA reports. Am J Psychiatry 2003; 160: 790–2
- Quitkin FM. Placebos, drug effects, and study design: A clinician's guide. Am J Psychiatry 1999; 156: 829–36
- Charney DS, Nemeroff CB, Lewis L, Laden SK, Gorman JM, Laska EM, et al. National Depressive and Manic-depressive Association consensus statement of the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry 2002; 59: 262–70
- Cutler RN, Sramek JJ, Kurtz NM. Anxiolytic compounds. Perspectives in drug development. John Wiley & Sons, New York 1996
- Keck PE, Welge JA, Strakowski SM, Arnold LM, McElroy SL. Placebo effect in randomised, controlled maintenance studies of patients with bipolar disorder. Biol Psychiatry 2000; 47: 756–61
- Keck PE, Welge JA, McElroy SL, Arnold LM, Strakowski SM. Placebo effect in randomised, controlled studies of acute bipolar mania and depression. Biol Psychiatry 2000; 47: 748–55